We diagnose to cure

Our blood-based approach unlocks true precision medicine

Learn more

Our blood-based platform unlocks true precision medicine

Big data diagnostics, AI, and therapeutics working in tandem for patients

Diagnostics

Blood-based diagnostics with multiomic data, including genomics and transcriptomics, provide a more detailed understanding of disease

Data + AI

Analyzing multiomic patient data from all stages leads to disease insights and novel targets

Therapeutics

A deeper understanding of disease biology unlocks new, better drug targets and medicines

Solving big problems in cancer care

Early interception + dynamic monitoring

Our blood-based platform is more sensitive and more informative than existing bone marrow tests for accurate diagnosis and earlier interception of disease. Ongoing monitoring through regular blood draws enables earlier detection of disease so physicians can respond sooner.

Personalized treatment guidance

Concise reports deliver actionable insights about which therapies are most likely  to succeed and maximize patients’ lives.

Harnessing patient data to make better medicines

We’re amassing the most comprehensive multiomic database in blood cancer, which we mine using AI to uncover insights into disease biology and potential novel therapies.

The Team

Predicta is guided by a veteran leadership team with decades of commercialization experience across genomics, oncology, and diagnostics.

Kate Caves

Kate Caves

CEO

Aparna Raval

Aparna Raval

SVP, Translational Research

Francois Aguet, PhD

Francois Aguet, PhD

Head of Computational Biology

Doron Lipson, PhD

Doron Lipson, PhD

CTO

The Board

 Mara Aspinall

Mara Aspinall

Partner, Illumina Ventures

Jay Wohlgemuth, MD

Jay Wohlgemuth, MD

Independent, Former CMO Quest Diagnostics

Ann DeWitt, PhD

Ann DeWitt, PhD

Partner, Engine Ventures

Kate Caves

Kate Caves

CEO

Irene Ghobrial, MD

Irene Ghobrial, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Scientific Co-founders

Predicta was founded by the world’s leading cancer genomics and multiple myeloma researchers from the Broad Institute and Dana Farber Cancer Institute – many are physician scientists who see patients every day.

Kenneth Anderson, MD

Kenneth Anderson, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Co-founder of C4 Therapeutics

Irene Ghobrial, MD

Irene Ghobrial, MD

Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School

Gad Getz, PhD

Gad Getz, PhD

Professor of Pathology, Mass General, Harvard Medical School, Co-founder of the Broad Institute and Scorpion Therapeutics

Keith Flaherty, MD

Keith Flaherty, MD

Professor of Medicine, Mass General, Harvard Medical School, Founder of Loxo Oncology, Strata Oncology, Scorpion Therapeutics

Romanos Sklavenitis-Pistofidis, MD, PhD

Romanos Sklavenitis-Pistofidis, MD, PhD

Instructor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School

Predicta is backed by leading life sciences investors

Contact us

Thank you

Your submission has been received.

Oops! Something went wrong while submitting the form.